Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APR-246 + Azacitidine Maintenance in TP53 Mutated AML/MDS Post-HSCT
NCT03931291Phase 2Completed
- Sponsor
- Aprea Therapeutics
- Start
- Sep 2019
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of eprenetapopt in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Aprea Therapeutics. Primary endpoint: Relapse-free Survival at 1 year. Started Sep 2019; status: completed.
02
Drugs
eprenetapopt
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT03931291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03931291.